TICKERNERD
Menu
ABUSABUSHealthcare · Biotechnology

ABUS Stock Forecast: Arbutus Biopharma Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.12
0.00% on the day

The 1 Wall Street analysts covering Arbutus Biopharma Corp. hold a median 12-month price target of $5.5 — +7.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
92 / 100
Median analyst target
$5.50
Analysts covering
1
Revenue$1.0M−90.6% y/y
Operating income−$5.8M
Net income−$5.1M
Free cash flow−$6.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
+9.6%
YTD
+6.4%
1Y
+4.5%
From 52W high
−1.9%
From 52W low
+39.5%
$3.67
$5.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABUS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arbutus Biopharma Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Quality
97
Value
96
Volatility
91
Momentum
79
Issuance
59
Revisions
54
Size
45
Accruals
19

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABUS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABUS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$4.50$5.00$5.50Oct 25Jan 26Apr 26Jul 26ABUSHigh $5.50Median $5.50Low $5.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $5.50Median $5.50High $5.50

The green dot is the last close — the median target sits +7.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Nov 2025Chardan CapitalMaintainsBuy$5.00
11 Aug 2025Chardan CapitalMaintainsBuy—
28 Mar 2025Chardan CapitalMaintainsBuy—
21 Jan 2025HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024Chardan CapitalMaintainsBuy—
18 Nov 2024HC Wainwright & Co.ReiteratesBuy—
7 Nov 2024Chardan CapitalMaintainsBuy—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Nov 2024Chardan CapitalMaintainsBuy$4.00 → $4.50
5 Sept 2024JefferiesMaintainsBuy—
2 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
7 June 2024HC Wainwright & Co.ReiteratesBuy—
6 June 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024Chardan CapitalMaintainsBuy—
3 May 2024Chardan CapitalReiteratesBuy—
4 Apr 2024JMP SecuritiesReiteratesMarket Outperform—
1 Mar 2024Chardan CapitalReiteratesBuy—
1 Mar 2024HC Wainwright & Co.MaintainsBuy—
12 Sept 2023HC Wainwright & Co.ReiteratesBuy—
4 Aug 2023Chardan CapitalReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABUS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABUS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Arbutus Biopharma Corp. returned +4.5% against +17.5% for the S&P 500, dividends included.

ABUS vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26ABUSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABUS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Arbutus Biopharma Corp. (ABUS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.5×

Cheaper than 64% of US stocks

Price / sales
5.6×

Cheaper than 23% of US stocks

Price / book
3.9×

Cheaper than 26% of US stocks

EV / EBITDA
6.3×

Cheaper than 51% of US stocks

Growth & margins
Revenue growth (YoY)
−90.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−90.6%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−567.2%

Higher than 7% of US stocks

Net margin
84.2%

Higher than 99% of US stocks

Returns & dividend
Return on equity
89.6%

Higher than 96% of US stocks

Return on assets
48.8%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arbutus Biopharma Corp. (ABUS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arbutus Biopharma Corp. has a market value of $1.0B and an enterprise value of $924.0M.

  • Revenue in the twelve months to 30 June 2026: $181.7M. The latest quarter shrank 90.6% year on year.

  • Net income over the same four quarters: $153.1M, a 84.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$24.6M.

  • Shares outstanding: 197.6M.

  • Trailing P/E: 6.5×; forward P/E: −31.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arbutus Biopharma Corp. employs 19 people — $9.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

ABUS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABUSArbutus Biopharma Corp.$1.0B
92
KURAKura Oncology, Inc.$1.0B
79
JANXJanux Therapeutics, Inc.$1.0B
70
MLTXMoonLake Immunotherapeutics$1.0B
15
ATTOAttovia Therapeutics, Inc.$1.0B
0
SVRASavara, Inc.$1.0B
35
FTHFaeth Therapeutics, Inc.$965.2M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arbutus Biopharma Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABUS news & analysis

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

GlobeNewsWire · 24 Aug 2026neutral

Arbutus Biopharma announced the commencement of a modified "Dutch Auction" tender offer to purchase for cancellation up to US$230 million in value of its common shares. The offer is set at a price between US$5.00 and US$5.75 per share and is detailed in the accompanying offer to purchase and issuer bid circular dated August 24, 2026.

Why it matters — ABUS watchers would care because this share repurchase program represents a capital allocation action that could reduce the company's outstanding share count.

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

GlobeNewsWire · 21 Aug 2026neutral

Arbutus Biopharma announced plans to commence a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares at a price between US$5.00 and US$5.75 per share. The offer is expected to start around August 24, 2026, expire around September 29, 2026, and be funded from the company's cash on hand.

Why it matters — ABUS watchers would care because the company is deploying a significant portion of its cash to repurchase shares, potentially affecting share count and the stock's trading dynamics.

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 12 Aug 2026neutral

Arbutus Biopharma reported its second quarter 2026 financial results and provided a corporate update. The company disclosed it maintained cash, cash equivalents and marketable securities of $92.6 million as of June 30, 2026.

Why it matters — ABUS watchers would note the company's cash position as an indicator of its financial runway for ongoing operations and pipeline development.

FAQ

Frequently asked questions about ABUS stock

What is the ABUS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Arbutus Biopharma Corp. have a median 12-month price target of $5.5, with estimates ranging from $5.5 to $5.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABUS stock a buy right now?

Of the 1 analysts covering Arbutus Biopharma Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arbutus Biopharma Corp. 92 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABUS?

As at 12 Sept 2026, Arbutus Biopharma Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will ABUS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +7.4% from the last close, and Ticker Nerd's factor model ranks Arbutus Biopharma Corp. 92 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABUS stock forecast for 2030?

No analyst covering Arbutus Biopharma Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.5 to $5.5 over the next 12 months.

How has ABUS stock performed over the past year?

Arbutus Biopharma Corp. returned +4.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arbutus Biopharma Corp. do?

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response.

What is the latest news on ABUS?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share". Arbutus Biopharma announced the commencement of a modified "Dutch Auction" tender offer to purchase for cancellation up to US$230 million in value of its common shares. The offer is set at a price between US$5.00 and US$5.75 per share and is detailed in the accompanying offer to purchase and issuer bid circular dated August 24, 2026.

Company

About Arbutus Biopharma Corp.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.

CEO Ms. Lindsay Androski J.D., M.B.A. · 19 employees · United States · https://www.arbutusbio.com